2006/018 100th NICE technology appraisal guidance offers new hope for people with colon cancer

The National Institute for Health and Clinical Excellence (NICE) has today (26 April 2006) published its 100^th technology appraisal guidance. The guidance to the NHS in England and Wales on the use of capecitabine and oxaliplatin for the adjuvant treatment of patients with stage III (Dukes' C)* colon cancer following surgery for the condition, recommends that the drugs should be considered as options for the adjuvant treatment of patients as follows:

• capecitabine as monotherapy
• oxaliplatin in combination with 5-fluorouracil and folinic acid.